Jay P. Powers - Arcus Biosci, Hayward, CA 94545 USA

基本信息

Career Trajectory

Bio

No content for now

Research Interests

Papers共 46 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

Discovery and Characterization of Potent, Selective, and Orally Bioavailable 7-Azaindazole AXL Receptor Tyrosine Kinase Inhibitors

Corinne N Foley, Shiwei Qu, Srinivas Reddy Paladugu,Manjunath Lamani, Rebecca Grange,Ehesan U Sharif,Joice Thomas, Pradeep Nareddy, Guiling Zhao, Yu Chen, Xiaoning Zhao,David Green, Hsin-Ting Huang,Lixia Jin, Susan L Paprcka, Ester Fernandez-Salas,Jay P Powers, Manmohan R Leleti, Dillon H Miles

Journal of medicinal chemistryno. 11 (2025): 10677-10703

Cited0Views0WOSBibtex

Stereodivergent Synthesis of the Vicinal Difluorinated Tetralin of Casdatifan Enabled by Ru-Catalyzed Transfer Hydrogenation

Guillaume Mata,Artur K. Mailyan,Jeremy Fournier,Joel W. Beatty,Manmohan R. Leleti,Jay P. Powers,Kenneth V. Lawson

ORGANIC LETTERSno. 3 (2025): 833-839

Cited1Views0WOSBibtex

Discovery of AB801, a Potent and Selective Inhibitor of AXL Receptor Tyrosine Kinase for Use in Cancer Therapy

Dillon H Miles,Manjunath Lamani, Srinivas Reddy Paladugu, Shiwei Qu, Corinne N Foley,Ehesan U Sharif,Joice Thomas, Pradeep Nareddy,Joel W Beatty, Balint Gal, Guiling Zhao, Rebecca Grange, Stefan G Shaqfeh,Ada Chen,Hema Singh, Yue Tong Lee, Xiaoning Zhao,David Green, Hsin-Ting Huang,Elaine Ginn,Lixia Jin, Susan L Paprcka, Ester Fernández-Salas, Lian Zhou, Jordon Johnson, Lilian Adeojo,Jay P Powers, Manmohan R Leleti

Journal of medicinal chemistryno. 11 (2025): 10663-10676

Cited0Views0WOSBibtex

Development of a Scalable Synthesis of Casdatifan (AB521), a Potent, Selective, Clinical-Stage Inhibitor of HIF-2α

Clayton Hardman,Artur K. Mailyan,Guillaume Mata,Joel W. Beatty,Samuel L. Drew,Jeremy Fournier,Jaroslaw Kalisiak,Brandon R. Rosen, Matthew Epplin,Balint Gal,Kai Yu,Zhang Wang, Karl Haelsig,Anh Tran,Manmohan R. Leleti,Jay P. Powers,Kenneth V. Lawson

ORGANIC PROCESS RESEARCH & DEVELOPMENT (2025)

Cited0Views0Bibtex

Abstract A012: Discovery and Characterization of Casdatifan (AB521), a Clinical-Stage, Potent, and Selective Hypoxia-Inducible Factor (Hif)-2Α Inhibitor

Kenneth V. Lawson,Artur Mailyan,Guillaume Mata,Joel W. Beatty,Samuel L. Drew,Jeremy T. A. Fournier,Jaroslaw Kalisiak, Ahn T. Tran,Kai Yu,Brandon R. Rosen, Clayton Hardman, Matthew Epplin,Kelsey E. Sivick,Dana Piovesan,Suan Liu, Elain Ginn,Cesar A. Meleza,Lisa Seitz,Tzuling Cheng,Amber Pham, Mohammad Ghasemi,Paul G. Foster,Matthew J. Walters,Manmohan Leleti,Jay P. Powers

Molecular Cancer Therapeuticsno. 12_Supplement (2024)

Cited0Views0Bibtex

Discovery and Characterization of Casdatifan (AB521), a Clinical-Stage, Potent, and Selective Hypoxia-Inducible Factor (Hif)-2Α Inhibitor

MOLECULAR CANCER THERAPEUTICSno. 12 (2024)

Cited0Views0Bibtex

Abstract A011: Discovery and Characterization of the First Highly Potent and Selective AXL Receptor Tyrosine Kinase Inhibitor AB801

Dillon H. Miles, Corinne N. Foley,Shiwei Qu,Srinivas Paladugu,Ehesan U. Sharif,Joice Thomas, Pradeep Nareddy, Guiling Zhao, Rebecca Grange,Manmohan R. Leleti,Jay P. Powers,Stefan Garrido-Shaqfeh,Ada Chen,Hema Singh, Yue Tong Lee,Xiaoning Zhao,David Green, Hsin-Ting Huang,Lixia Jin, Jhansi Leslie, Logan Chinn,Susan L Paprcka,Ester Fernandez-Salas

Molecular Cancer Therapeuticsno. 12_Supplement (2024)

Cited0Views0Bibtex

Discovery and Characterization of the First Highly Potent and Selective AXL Receptor Tyrosine Kinase Inhibitor AB801

MOLECULAR CANCER THERAPEUTICSno. 12 (2024)

Cited0Views0Bibtex

Abstract PR001: Discovery of Etrumadenant, a First-in-class Dual A2a and A2b Adenosine Receptor Antagonist for Cancer Immunotherapy

Ehesan U. Sharif,Dillon H. Miles,Brandon R. Rosen,Joel Beatty,Jenna L. Jeffrey,Laurent P. P. Debien,Rhiannon Thomas-Tran,Debashis Mandal, Dan Direnzo,Sachie Marubayashi,Kristen Zhang,Ferdie Soriano,Elaine Ginn,Divyank Soni, Pei-Yu Chen,Lixia Jin,Steve W. Young,Matt J. Walters,Manmohan R. Leleti,Jay P. Powers

Molecular Cancer Therapeuticsno. 12_Supplement (2024)

Cited0Views0Bibtex

Discovery of Etrumadenant, a First-in-class Dual A2a and A2b Adenosine Receptor Antagonist for Cancer Immunotherapy

MOLECULAR CANCER THERAPEUTICSno. 12 (2024)

Cited0Views0Bibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn